Antithrombotic Therapy Duration after Patent Foramen Ovale Closure for Stroke Prevention: Impact on Long-Term Outcome

Table 2

Periprocedural outcome.

Characteristic		Before PS matching				After PS matching
		All	Gr short	Gr long		Gr short	Gr long
		N = 259	N = 88	N = 171	value	N = 86	N = 86	value
Delay between stroke and cath (days)	median [IQR]	232 [137–420]	214 [127–360]	241 [150–440]	0.46	214 [127–365]	243 [153–434]	0.49
Atrial septal aneurysm	n (%)	152 (59)	47 (53)	105 (61)	0.23	46 (53)	52 (60)	0.44
Prosthesis type; size (mm)
Amplatzer; 25 [25–30]	n (%)	105 (41)	32 (36)	73 (43)	0.35	32 (37)	29 (34)	0.75
Cardia Star; 30 [25–30]	n (%)	99 (38)	37 (42)	62 (36)	0.42	36 (42)	35 (41)	1.00
Starflex; 28 [28–33]	n (%)	11 (4)	6 (7)	5 (3)	0.19	6 (7)	2 (2)	0.28
Gore; 28 [25–30]	n (%)	6 (2)	1 (1)	5 (3)	0.67	1 (1)	3 (3)	0.62
Premere; 25 [25–25]	n (%)	13 (5)	2 (2)	11 (6)	0.23	2 (2)	7 (8)	0.17
Occlutech; 25 [25–30]	n (%)	23 (9)	9 (10)	14 (8)	0.65	8 (9)	9 (10)	1.00
PFM Nit Occlud; 22 [22–25]	n (%)	2 (1)	1 (1)	1 (1)	1.00	1 (1)	1 (1)	1.00
Prosthesis size (mm)	median [IQR]	25 [25–30]	25 [25–30]	25 [25–30]	0.21	25 [25–30]	25 [25–30]	0.35
Complication	n (%)	9 (3)	2 (2)	7 (4)	0.72	2 (2)	5 (6)	0.44
Minor vascular	n (%)	2 (1)	0	2 (1)	0.55	0	0	—
Minor bleeding	n (%)	4 (2)	1 (1)	3 (2)	1.00	1 (1)	3 (3)	0.62
Non disabling stroke	n (%)	1 (0.3)	0	1 (1)	1.00	0	1 (1)	1.00
Transient ischemic attack	n (%)	0	0	0	—	0	0	—
Transient ST segment modification	n (%)	1 (0.3)	0	1 (1)	1.00	0	1 (1)	1.00
Death	n (%)	0	0	0	—	0	0	—
Transient atrial fibrillation	n (%)	1 (0.3)	1 (1)	0	1.00	1 (1)	0	1.00
Antithrombotic treatment at discharge
Aspirin	n (%)	164 (63)	54 (61)	110 (64)	0.68	54 (63)	52 (60)	0.87
Clopidogrel	n (%)	5 (2)	1 (1)	4 (2)	0.66	1 (1)	2 (2)	1.00
Dual antiplatelet therapy	n (%)	87 (33.5)	32 (36)	55 (32)	0.58	30 (35)	30 (35)	1.00
Anticoagulants	n (%)	1 (0.5)	1 (1)	0	0.34	1 (1)	0	1.00
Aspirin + anticoagulants	n (%)	2 (1)	0	2 (1)	0.55	0	2 (2)	0.50

Gr = Group; IQR = interquartile range; PS = propensity score.